Kairos Pharma Recognized for Innovative Approach to Cancer Drug Resistance at 2026 Pinnacle Awards

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, has been named an Emerald honoree at the 2026 Pinnacle Awards for Healthcare, recognized for its innovative approach to addressing cancer drug resistance. The company's strategy centers on resistance-modulating treatments, including its lead candidate ENV-105 (carotuximab), designed to inhibit tumor resistance pathways and enhance the effectiveness of existing therapies. This recognition matters because drug resistance represents one of the most significant challenges in oncology, often rendering initially effective treatments useless as cancers evolve and develop mechanisms to survive therapeutic attacks. The implications of this announcement are substantial for cancer patients, healthcare providers, and the broader medical community, as overcoming resistance could dramatically improve treatment outcomes and survival rates across multiple cancer types.

The company's lead candidate, ENV-105, is an antibody that targets CD105—a protein identified as a key driver of resistance and disease relapse in response to standard therapy. By targeting CD105, ENV-105 aims to reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for non-small cell lung cancer aimed at addressing significant unmet medical needs. As of the date of this press release, ENV-105 has not been approved as safe or effective by the United States Food and Drug Administration or any other comparable foreign regulator. The latest news and updates relating to KAPA are available in the company's newsroom at https://ibn.fm/KAPA.

This award recognition highlights the growing importance of resistance-modulating approaches in cancer treatment, particularly as combination therapies become increasingly central to oncology practice. The company's focus on structural biology to overcome drug resistance and immune suppression in cancer represents a forward-thinking approach that could potentially transform how cancers are treated long-term. The announcement is important because it validates the scientific approach behind Kairos Pharma's research and development efforts, potentially accelerating interest and investment in resistance-modulating technologies. For patients facing cancers that have become resistant to standard treatments, this recognition offers hope that new therapeutic options may emerge from this research direction. The full press release can be viewed at https://ibn.fm/ghPJC.

The implications extend beyond the immediate recognition, potentially influencing research priorities across the biopharmaceutical industry and encouraging more investment in resistance-focused therapeutics. As cancer continues to be a leading cause of death worldwide, with drug resistance contributing significantly to treatment failure and mortality, approaches like those being developed by Kairos Pharma could represent a paradigm shift in how cancers are managed. The company's advancement of combination approaches aimed at improving durability of response across multiple cancer indications suggests a comprehensive strategy that could benefit diverse patient populations. This award serves as an important milestone in the validation of resistance-modulation as a viable and necessary approach in the ongoing battle against cancer, potentially paving the way for more durable and effective treatment regimens that could significantly improve patient outcomes and quality of life.